Published in J Clin Oncol on March 02, 2009
Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst (2012) 1.07
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab (2010) 1.00
Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open (2014) 0.98
Anxiety level of early- and late-stage prostate cancer patients. Prostate Int (2013) 0.88
A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer. Biomed Res Int (2014) 0.82
Changing Patterns of Primary Treatment in Korean Men with Prostate Cancer Over 10 Years: A Nationwide Population Based Study. Cancer Res Treat (2015) 0.81
A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis (2014) 0.79
Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma. Int Urol Nephrol (2013) 0.77
The impact of numeracy on verbatim knowledge of the longitudinal risk for prostate cancer recurrence following radiation therapy. Med Decis Making (2014) 0.75
High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? Ann Oncol (2015) 0.75
Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management. World J Urol (2016) 0.75
The hospital anxiety and depression scale. Acta Psychiatr Scand (1983) 121.58
The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res (2002) 22.73
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 6.84
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst (2006) 3.10
A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol (2001) 2.91
Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer (2006) 2.42
The Intolerance of Uncertainty Scale: psychometric properties of the English version. Behav Res Ther (2002) 2.13
The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol (2007) 1.91
The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer. Cancer (2003) 1.91
Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst (2000) 1.75
Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology (2003) 1.73
The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer (2005) 1.59
Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes (2007) 1.49
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol (2004) 1.44
Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology (2008) 1.15
Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC). Psychosomatics (2006) 1.10
The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology (2001) 1.09
Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer (2007) 1.07
Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc (2006) 1.04
The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male (2006) 0.92
Extending the validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) at the time of prostate biopsy in a racially-mixed population. Psychooncology (2007) 0.90
The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol (2003) 0.88
Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev (2002) 0.86
High risk biochemical relapse and the timing of androgen deprivation therapy. J Urol (2006) 0.79
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst (2007) 5.13
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer (2011) 3.54
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2005) 3.28
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer (2012) 2.98
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol (2009) 2.69
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol (2011) 2.46
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res (2010) 2.44
A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol (2009) 2.26
International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol (2014) 2.13
Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol (2003) 2.12
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol (2011) 2.10
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res (2009) 1.93
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol (2008) 1.74
Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int (2007) 1.72
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer (2011) 1.70
Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology (2010) 1.70
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer (2009) 1.70
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res (2008) 1.68
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology (2010) 1.65
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Age-related trends in utilization and outcome of open and endovascular repair for abdominal aortic aneurysm in the United States, 2001-2006. J Vasc Surg (2009) 1.63
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant (2006) 1.63
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res (2005) 1.59
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol (2002) 1.56
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging (2004) 1.54
Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations. Magn Reson Med (2004) 1.50
Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol (2011) 1.45
MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology (2013) 1.38
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol (2012) 1.37
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs (2007) 1.37
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res (2009) 1.30
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol (2008) 1.29
Multiple reference tissue method for contrast agent arterial input function estimation. Magn Reson Med (2007) 1.27
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer (2010) 1.23
FYN is overexpressed in human prostate cancer. BJU Int (2008) 1.22
Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res (2005) 1.21
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol (2013) 1.21
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol (2004) 1.20
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res (2013) 1.19
Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst (2011) 1.17
Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology (2008) 1.15
Geriatric assessment improves prediction of surgical outcomes in older adults undergoing pancreaticoduodenectomy: a prospective cohort study. Ann Surg (2014) 1.14
Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. J Am Med Inform Assoc (2011) 1.12
Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res (2012) 1.11
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs (2010) 1.09
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2014) 1.09
Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer (2007) 1.07
Patients' barriers to receipt of cancer care, and factors associated with needing more assistance from a patient navigator. J Natl Med Assoc (2011) 1.06
Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer (2004) 1.06
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology (2011) 1.06
Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer (2007) 1.03
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int (2010) 1.03
Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol (2013) 1.03
Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res (2004) 1.02
Information-seeking styles among cancer patients before and after treatment by demographics and use of information sources. J Health Commun (2009) 0.99
Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med (2009) 0.97
Mentoring junior faculty in geriatric oncology: report from the Cancer and Aging Research Group. J Clin Oncol (2008) 0.97
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res (2005) 0.96
Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit Rev Oncol Hematol (2010) 0.96
Can induced anxiety from a negative earlier experience influence vascular surgeons' statistical decision-making? A randomized field experiment with an abdominal aortic aneurysm analog. J Am Coll Surg (2006) 0.96
Geriatric assessment in older patients with breast cancer. J Natl Compr Canc Netw (2009) 0.95
Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate (2011) 0.95
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer (2013) 0.94
Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. Urology (2011) 0.93
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs (2011) 0.93
Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men. Support Care Cancer (2010) 0.93
Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures. J Am Med Inform Assoc (2011) 0.93
Self-reported cancer screening among elderly Medicare beneficiaries: a rural-urban comparison. J Rural Health (2012) 0.93
A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol (2005) 0.92
Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys (2012) 0.91
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology (2010) 0.91
Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol (2015) 0.91
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int (2007) 0.91
Patient and provider determinants of nephrology referral in older adults with severe chronic kidney disease: a survey of provider decision making. BMC Nephrol (2011) 0.91
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU Int (2008) 0.91
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res (2004) 0.90
Low-grade prostate cancer diverges early from high grade and metastatic disease. Cancer Sci (2014) 0.90